MAPT and Alzheimer disease: In an Aβ1-42-induced AD experiment, it was found that senegenin can reduce the expression of GSK-3β and CDK-5, up-regulate the activity of PP-1 and PP-2A, and in-hibit the abnormal phosphorylation of tau (Chen Y. et al., 2012).